Open Access
Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
Jiajie Zhu
1
,
Haiyan Zhang
2
,
Qinghong Lin
1
,
Jingting Lyu
1
,
Lu Lu
1
,
Hanxi Chen
1
,
Xu-ning Zhang
1
,
Yanjun Zhang
3
,
Ke-Da Chen
1
1
Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
|
3
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
|
Publication type: Journal Article
Publication date: 2022-04-08
scimago Q1
wos Q1
SJR: 1.190
CiteScore: 8.6
Impact factor: 5.1
ISSN: 11778881
PubMed ID:
35450403
Drug Discovery
Pharmacology
Pharmaceutical Science
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently poses a threat to human health. 3C-like proteinase (3CLpro) plays an important role in the viral life cycle. Hence, it is considered an attractive antiviral target protein. Whole-genome sequencing showed that the sequence homology between SARS-CoV-2 3CLpro and SARS-CoV 3CLpro is 96.08%, with high similarity in the substrate-binding region. Thus, assessing peptidomimetic inhibitors of SARS-CoV 3CLpro could accelerate the development of peptidomimetic inhibitors for SARS-CoV-2 3CLpro. Accordingly, we herein discuss progress on SARS-CoV-2 3CLpro peptidomimetic inhibitors. Inflammation plays a major role in the pathophysiological process of COVID-19. Small-molecule compounds targeting 3CLpro with both antiviral and anti-inflammatory effects are also briefly discussed in this paper.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Scientific Reports
3 publications, 7.5%
|
|
|
Journal of Molecular Modeling
2 publications, 5%
|
|
|
International Journal of Molecular Sciences
2 publications, 5%
|
|
|
Biomaterials Research
1 publication, 2.5%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 2.5%
|
|
|
MedComm
1 publication, 2.5%
|
|
|
Biochemical Journal
1 publication, 2.5%
|
|
|
Scientific African
1 publication, 2.5%
|
|
|
Frontiers in Microbiology
1 publication, 2.5%
|
|
|
Journal of Peptide Science
1 publication, 2.5%
|
|
|
Molecules
1 publication, 2.5%
|
|
|
Journal of Chemical Information and Modeling
1 publication, 2.5%
|
|
|
Expert Opinion on Drug Discovery
1 publication, 2.5%
|
|
|
iScience
1 publication, 2.5%
|
|
|
Voprosy Virusologii
1 publication, 2.5%
|
|
|
Applied Biological Chemistry
1 publication, 2.5%
|
|
|
Microbiology Research
1 publication, 2.5%
|
|
|
Drug Discovery Today
1 publication, 2.5%
|
|
|
RSC Medicinal Chemistry
1 publication, 2.5%
|
|
|
Journal of Traditional and Complementary Medicine
1 publication, 2.5%
|
|
|
Current Medicinal Chemistry
1 publication, 2.5%
|
|
|
Acta Pharmaceutica Sinica B
1 publication, 2.5%
|
|
|
Bioscience Reports
1 publication, 2.5%
|
|
|
Journal of Molecular Graphics and Modelling
1 publication, 2.5%
|
|
|
Pathogens
1 publication, 2.5%
|
|
|
ChemistrySelect
1 publication, 2.5%
|
|
|
RSC Advances
1 publication, 2.5%
|
|
|
Mendeleev Communications
1 publication, 2.5%
|
|
|
3 Biotech
1 publication, 2.5%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Springer Nature
9 publications, 22.5%
|
|
|
Elsevier
8 publications, 20%
|
|
|
MDPI
6 publications, 15%
|
|
|
Wiley
3 publications, 7.5%
|
|
|
Taylor & Francis
3 publications, 7.5%
|
|
|
Portland Press
2 publications, 5%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 5%
|
|
|
Frontiers Media S.A.
1 publication, 2.5%
|
|
|
American Chemical Society (ACS)
1 publication, 2.5%
|
|
|
Central Research Institute for Epidemiology
1 publication, 2.5%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.5%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 2.5%
|
|
|
ifmbe proceedings
1 publication, 2.5%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
40
Total citations:
40
Citations from 2025:
10
(25%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Zhu J. et al. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds // Drug Design, Development and Therapy. 2022. Vol. Volume 16. pp. 1067-1082.
GOST all authors (up to 50)
Copy
Zhu J., Zhang H., Lin Q., Lyu J., Lu L., Chen H., Zhang X., Zhang Y., Chen K. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds // Drug Design, Development and Therapy. 2022. Vol. Volume 16. pp. 1067-1082.
Cite this
RIS
Copy
TY - JOUR
DO - 10.2147/dddt.s359009
UR - https://doi.org/10.2147/dddt.s359009
TI - Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
T2 - Drug Design, Development and Therapy
AU - Zhu, Jiajie
AU - Zhang, Haiyan
AU - Lin, Qinghong
AU - Lyu, Jingting
AU - Lu, Lu
AU - Chen, Hanxi
AU - Zhang, Xu-ning
AU - Zhang, Yanjun
AU - Chen, Ke-Da
PY - 2022
DA - 2022/04/08
PB - Taylor & Francis
SP - 1067-1082
VL - Volume 16
PMID - 35450403
SN - 1177-8881
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Zhu,
author = {Jiajie Zhu and Haiyan Zhang and Qinghong Lin and Jingting Lyu and Lu Lu and Hanxi Chen and Xu-ning Zhang and Yanjun Zhang and Ke-Da Chen},
title = {Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds},
journal = {Drug Design, Development and Therapy},
year = {2022},
volume = {Volume 16},
publisher = {Taylor & Francis},
month = {apr},
url = {https://doi.org/10.2147/dddt.s359009},
pages = {1067--1082},
doi = {10.2147/dddt.s359009}
}